Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Expenses (2016 - 2025)

Rocket Pharmaceuticals' Operating Expenses history spans 10 years, with the latest figure at $44.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 29.88% year-over-year to $44.0 million; the TTM value through Dec 2025 reached $231.7 million, down 15.17%, while the annual FY2025 figure was $231.7 million, 15.17% down from the prior year.
  • Operating Expenses for Q4 2025 was $44.0 million at Rocket Pharmaceuticals, down from $52.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $73.7 million in Q2 2024 and bottomed at $34.0 million in Q2 2021.
  • The 5-year median for Operating Expenses is $62.4 million (2023), against an average of $57.8 million.
  • The largest annual shift saw Operating Expenses soared 81.28% in 2021 before it dropped 29.88% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $44.3 million in 2021, then surged by 55.83% to $69.1 million in 2022, then fell by 8.4% to $63.3 million in 2023, then dropped by 0.92% to $62.7 million in 2024, then decreased by 29.88% to $44.0 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Operating Expenses are $44.0 million (Q4 2025), $52.2 million (Q3 2025), and $71.1 million (Q2 2025).